Evaluate of clinical efficacy and economics of imitation and original voriconazole in the treatment of invasive fungal disease in patients with hematological malignancies

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019383

Enrollment

Unknown

Registered

2018-11-08

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive fungal disease

Interventions

Group 1:Application of original voriconazole injection

Group 2:Application of imitation voriconazole injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) patients diagnosed as hematological malignancies; (2) received voriconazole injection during hospitalization; (3) do not limit sex, age and course of disease.

Exclusion criteria

Exclusion criteria: (1) non malignant hematologic diseases or patients with unclear diagnosis; (2) patients who did not receive voriconazole injection or combined with other antifungal agents during single hospitalization.

Design outcomes

Primary

Measure	Time frame
Histopathological examination;Microbiological examination;Blood fungal culture test;Blood antigen detection;temperature;blood routine examination;CT examination;tracheoscopy;coagulation function;liver function;Renal function;Microbial dynamic fungal detection;Hemobacterium culture;cost;	—

Countries

China

Contacts

Public ContactZhengxiang Li

Tianjin Medical University General Hospital

13820893896@163.com+86 13820893896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026